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Objective: The primary purpose of this randomized controlled trial study was to compare clinical preg-
nancy rates and ovulation parameters in female patients of unexplained infertility undergoing intrauterine
insemination (IUI) using an antagonist protocol versus a conventional clomiphene citrate protocol.
Materials and methods: This was a multicenter parallel randomized controlled, open-label trial. A central
randomization center used computer generated tables to allocate treatments. We conducted the study in
two centers: Saudi Center and Samir Abbas and Assisted Reproductive Techniques Center of Cairo Uni-
versity, Cairo, Egypt between January 2011 and January 2014. Six hundred and twenty-two couples with
unexplained infertility were randomized into two equal groups with 27 excluded after randomization:
the antagonist protocol group and the clomiphene group. Antagonist protocol: human menopausal go-
nadotropins were given to 298 patients from Day 2 to reach a dominant follicle of 18e22 mm, intra-
muscularly. Then, orgalutrone (0.25 mg) was subcutaneously started from Day 6 or Day 7 until the day of
human chorionic gonadotropins (hCG; that was given in the dose of 10,000 IU, intramuscularly) when
follicles reached 18e22 mm. Afterward, the IUI of 0.5 mL was done from 34 hours to 36 hours using IUI
catheter without guidance of ultrasonography and with an empty urinary bladder. The clomiphene
citrate protocol was clomiphene citrate given 100 mg/d to 297 patients from Day 2 to Day 6 and follow
up until day of hCG. The clinical pregnancy rate detected with ultrasound conﬁrmed fetal heart pulsa-
tions at 6-weeks' gestation (4 weeks after IUI). The number of dominant follicles, level of serum estradiol,
and luteinizing hormone at the day of hCG injection and the incidence of twin or triplet pregnancies in
both groups were secondary outcome measures.
Results: The clinical pregnancy rate in the antagonist protocol group was signiﬁcantly (p < 0.001) higher
than in the clomiphene group. It was 80 patients (27%) in the antagonist protocol group versus 41 pa-
tients (14%) in the clomiphene group. The mean number of dominant follicles was signiﬁcantly
(p < 0.001) greater in the antagonist protocol group (4.36 ± 1.36 dominant follicles) compared with the
clomiphene group (2.71 ± 0.96 dominant follicles). In addition, the rate of twin pregnancies was 15 cases
in the antagonist protocol group versus six cases only in the clomiphene group (p ¼ 0.047). The lutei-
nizing hormone also was signiﬁcantly lower in the antagonist group (2.1 ± 1.3) compared with that in the
clomiphene group (9.5 ± 3.6).
Conclusion: IUI clinical pregnancy rates were signiﬁcantly higher by antagonist protocol.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).lmanyal, Egypt.
hy).
bstetrics & Gynecology. PublishedIntroduction
Results of intrauterine insemination (IUI) done in natural
menstrual cycles are subtle [1,2]. That is why most clinics use IUI in
controlled ovarian hyperstimulation cycles. In addition, there is
inadequate evidence to recommend or advise against IUI, eitherby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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timed intercourse or the reverse [3].
However, the need for IUI is still high because the prevalence of
unexplained infertility is up to 20% for couples after the initial
diagnostic workup. This number may increase if cases of mild male
infertility added to it [4].
Superovulation with usual doses of gonadotropins induces
pregnancy in 10e15% of couples, as stated by large clinical
trials [1,5,6]. The drawbacks of this method were an increase
in the incidences of twin pregnancy (15e20%) and triplets
(5e10%), thus rendering IUI as an unsafe technique in stimu-
lated cycles [5e11]. It is a simple, noninvasive, and non-
expensive method in assisted reproductive techniques but
with a low pregnancy rate.
Many studies have proved the value of gonadotropin-releasing
hormone antagonist as an effective method to prevent premature
luteinization. However, most of these studies failed to ﬁnd a sig-
niﬁcant improvement in clinical pregnancy rates in ovarian in-
duction IUI cycles [12].
Hence, the rationale intended for this randomized controlled
study was to test the hypothesis that the antagonist protocol can
lead to a higher rate of pregnancy in patients with unexplained
infertility undergoing IUI, than the standard or the most common
protocol using clomiphene citrate without premature rise of
luteinizing hormone (LH).
Materials and methods
The study was conducted in the Saudi centers Samir Abbass and
Assisted Reproductive Techniques Center of Cairo University, Cairo,
Egypt during the period from January 2011 to January 2014.
Ethics
This study followed the principles of the Declaration of Helsinki
and in accordance with the Medical Research Involving Human
Subjects Act, and was approved by the Medical Ethical Review
Committee of Cairo University and Samir Abbas Ethical Committees.
The purpose of this study was clearly explained in Arabic lan-
guage to all participants before their enrolment to the study, and an
informed consent form was signed by and obtained from all of
those enrolled.
We recruited to this study couples with unexplained infer-
tility that were eligible to undergo IUI. Criteria of unexplained
infertility was as follows: (1) women with a body mass index
18e30 kg/m2 with unexplained infertility; with (2) conﬁrmed
bilateral patent fallopian tubes (hysterosalpingography or lapa-
roscopy); in addition to (3) normal ovulation evidenced by
midluteal serum progesterone > 10 ng/mL and regular menstrual
cycles; and ﬁnally (4) husband semen analysis with mean sperms
count > 15 million sperm/m:, motility > 32%, and
morphology > 4% normal form [13].
Female patients with bilateral tubal block, uterine distorted
anatomy (submucous ﬁbroids or Asherman syndrome), and
hydrosalpinx were not included. In addition, female patients with
hyperprolactinemia or thyroid dysfunction were excluded.
All eligible patients were randomized into the two study groups
using the matched pairs randomized block design based on age and
period of infertility. The two study groups were the antagonist
protocol group and the clomiphene citrate protocol group.
Procedures
All enrolled patients were subjected to a full history taking,
general and local examination. Hormonal proﬁle and pelvicultrasound were done for female patients and semen analysis after
4e7 days of abstinence was done for male patients.
Women assigned to the clomiphene group were given clomi-
phene citrate (Clomid, Sanoﬁ-Aventis, Bourgoin-Jallieu, France)
100 mg from Day 2 to Day 6. Then, the monitoring of ovulation was
continueduntil thedominant follicle (DF)was18e22mm.Hence, LH
and estradiol were measured, and human chorionic gonadotropin
(hCG; Choriomon; IBSA, Lugano, Switzerland)was given at a dose of
10,000 IU, intramuscularly. Afterwards, IUI of 0.5 mLwas done from
34 hours to 36 hours, using an IUI catheter without guidance of ul-
trasonography and with an empty urinary bladder.
However, women assigned to the antagonist protocol group
were given human menopausal gonadotropins (Merional; IBSA)
from Day 2 to reach a DF of 18e22 mm. The LH was then
measured and ganirelix acetate (Orgalutrone; Merck Sharp &
Dohme, Quebec, Canada) 0.25 mg subcutaneously was started
from Day 6 or Day 7 until the day of hCG that was given in the
dose of 10,000 IU intramuscularly when follicles reached
18e22 mm. Afterwards, the IUI of 0.5 mL was done from 34 hours
to 36 hours using an IUI catheter without guidance of ultraso-
nography and with an empty urinary bladder. The aims of these
modiﬁcations were to avoid premature LH surge and to ensure a
high oocyte count available at the time of insemination. Both
groups had the same luteal phase support by cyclogest 400 mg
vaginal suppository for 2 weeks.
The primary end point was clinical pregnancy rate, as detected
by the presence of an intrauterine sac with positive heart pulsations
at 6-weeks' gestation done at 4 weeks after IUI in each group. The
secondary end points were the number of DFs, levels of LH, and
serum estradiol at the day of hCG injection and the incidence of
twin or triplet pregnancy in both groups.
Statistical analysis
All statistical tests were done using a signiﬁcance level of
95%. A value for p < 0.05 was considered statistically signiﬁ-
cant. SPSS software (version 20.0, SSPS Inc., Chicago, IL, USA)
was used for the statistical analyses. Data were presented as
mean ± standard deviation for continuous variables and as
frequency and percent for categorical variables. Comparisons
between the two groups were done using Pearson Chi-square
test for categorical variable and the unpaired Student t test for
continuous variables.
A sample size calculation was done to calculate the number of
patients needed in each group, with an alpha level < 0.05 and
power > 90%. The sample size used was sufﬁcient to achieve a
power more than 90%.
Results
All patients (655) who came to the centers were asked to
participate in the study. Twenty-three patients refused to partici-
pate, and 10 patients were excluded before randomization for
different causes; thus, leaving a population of 622 eligible patients
who were randomized in this trial. Twenty-seven patients were
excluded after randomization. The dispositions of these patients
are shown in Figure 1.
Baseline characteristics
Six hundred and twenty-two couples suffering from infertility
were enrolled in this study, after being randomly assigned to two
groups, 311 in each. Only 595 patients were included in the anal-
ysis. There was no statistically signiﬁcant difference (p > 0.05) be-
tween both groups regarding the age, duration, and type of
All paƟents with unexplained inferƟlity 
aƩending the center (screened)
N = 655




23 refused to participate
10 excluded
7 patients: subfertile





PP = 297 PP = 298
13 patients excluded due to:
2 took the antagonist protocol at
improper time or missed dose
4 noncompliant to treatment
2 missing US for triggering hCG
3 failure to retrieve the sample
2 noncooperative during IUI
14 patients excluded due to:
5 failure to retrieve the sample
5 noncompliant to treatment
2 missing US for triggering hCG
2 noncooperative during IUI
Figure 1. Consort diagram. hCG ¼ human chorionic gonadotropins; IUI ¼ intrauterine insemination; PP ¼ per protocol; US ¼ ultrasound.
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and motility), as shown in Table 1, respectively. Also, there was a no
statistically signiﬁcant difference (p > 0.05) between both groups
regarding the mean progressive motility percent before processing,
as shown in Table 1.
Semen quality before and after preparation
We conducted only one trial of IUI therapy for candidates in both
groups. There was no statistically signiﬁcant difference in semen
quality in terms of concentration (p > 0.05), progressive motility
(p > 0.05), and morphology between the two study groups either
before or after preparation, as shown in Table 1. Before preparation,
the mean semen concentration in the antagonist protocol group
was 38.98 ± 9.18 million and in the clomiphene group was
39.92 ± 10.47 million (p ¼ 0.124). After preparation, the mean
semen concentration was 23.46 ± 8.32 million in the antagonist
protocol group and 24.87 ± 7.80 million in the clomiphene group
(p ¼ 0.554). Additionally, the progressive motility before prepara-
tion in the antagonist protocol group 40.51 ± 8.35% and the
clomiphene groupwas 39.55 ± 6.96% (p¼ 0.234). After preparation,the progressive motility in the antagonist protocol group
89.20 ± 5.28% and the clomiphene group was 90.52 ± 3.65%
(p ¼ 0.117), as shown in Table 1.
Primary outcome of the study
The number and rate of clinical pregnancy as determined by the
presence of fetal heart pulsations at 6-weeks' gestation was 80
patients (27%) in the antagonist protocol group and 41 patients
(14%) in the clomiphene group, (p ¼ 0.000); as shown in Table 1.
Secondary outcomes of the study
The mean number of DFs was greater in the antagonist protocol
group (4.36 ± 1.36 DF) comparedwith that of the clomiphene group
(2.71 ± 0.96 DF). Statistically, this difference is very highly signiﬁ-
cant with p < 0.001. In addition, there was a highly signiﬁcant
difference detected between both groups regarding estrogen level
at hCG day, as shown in Table 1. LH also was signiﬁcantly lower in
antagonist group (2.1 ± 1.3) compared with that in the clomiphene
group (9.5 ± 3.6; p < 0.001).
Table 1
Patient characteristics and study outcomes.
Antagonist protocol Clomiphene citrate protocol p
N ¼ 298 N ¼ 297
Age (y) 30.4 (5.72) 30.06 (5.00) 0.442
Infertility duration (y) 5.66 (2.21) 5.38 (2.72) 0.396
BMI 24.2 (3.1) 24.3 (3.3) 0.243
Infertility type
Primary 187 (62.75) 190 (63.97) 0.757
Secondary 111 (37.25) 107 (36.03)
Semen concentration before preparation (in millions) 38.98 (9.18) 39.92 (10.47) 0.124
Progressive motility before preparation 40.51 (8.35) 39.55 (6.96) 0.234
Morphology (% of normal forms) 44 (10.4) 45 (14.3) 0.390
Semen concentration after preparation (in millions) 23.46 (8.32) 24.87 (7.80) 0.554
Progressive motility after preparation 89.20 (5.28) 90.52 (3.65) 0.117
Clinical pregnancy rate 80 (27) 41 (14) <0.001
Twins 15 (5) 6 (2) 0.047
No. of dominant follicles 4.36 (1.36) 2.71 (0.96) <0.001
Estradiol level at hCG d 902.62 (305.48) 494.80 (226.12) <0.001
LH at d of hCG 2.1 (1.3) 9.5 (3.6) <0.001
Direct cost of 1 cycle in Saudi Rials 1600 ± 200 50 ± 20 <0.001
Mild ovarian hyperstimulation 30 (10) 6 (2) <0.001
Severe ovarian hyperstimulations 0 0 d
Data are presented as n (%) or mean ± standard deviation.
BMI ¼ body mass index; hCG ¼ human chorionic gonadotropin; LH ¼ luteinizing hormone.
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both groups in the rate of twin pregnancies, where the number of
twin pregnancies in the antagonist protocol group were 15
compared with six cases only in the clomiphene group (p ¼ 0.047),
as shown in Table 1. Moreover, both groups showed no triplet
pregnancies.
Mild ovarian hyperstimulation syndrome (OHSS) occurred in 30
(10%) of the antagonist protocol group versus six (2%) of the
clomiphene group (p < 0.001). No severe OHSS occurred in both
groups.
In addition, the antagonist protocol has a very high direct cost
[1600 ± 200 Saudi Rials (SR)] compared with only (50 ± 20 SR) for
the clomiphene protocol.Discussion
The current study showed that there is a signiﬁcant increase in
the rate of clinical pregnancies in the antagonist protocol arm
versus the clomiphene citrate arm. Secondary outcomes showed a
very highly signiﬁcant increase both in the level of serum estradiol
at the day of hCG and the number of DFs, favoring the arm of
antagonist protocol. There is also a marked signiﬁcant reduction in
LH level before hCG in the antagonist group. Moreover, the twin
pregnancy rate was higher in the antagonist protocol arm than in
the clomiphene citrate arm. This was evident as there were 80
patients (27%) of the antagonist protocol and only 41 patients (14%)
of the clomiphene group who proved to be pregnant. In addition,
the mean serum LH was signiﬁcantly lower in the antagonist group
(2.1 ± 1.3) compared with the clomiphene group (9.5 ± 3.6).
Moreover, the mean serum estradiol on the day of hCG was
902.62 pg/dL in the antagonist protocol group compared with
494.80 pg/dL in the clomiphene group. Moreover, the mean num-
ber of DFs was 4.36 in the antagonist protocol group versus 2.71 in
the clomiphene citrate group.
To the best of our knowledge of the literature, this is the ﬁrst
study to compare the antagonist protocol with clomiphene citrate.
The results of this study are in favor of the antagonist protocol.
Moreover, the rationale behind the hypothesis that the antagonist
protocol would increase the rate of clinical pregnancy by increasing
the number of follicles and serum estradiol at the day of hCG waswell met in our study. In addition, reduced LH in the antagonist
group supports that gonadotropin-releasing hormone antagonist
has a strong effect on pituitary suppression and prevention of
premature luteinization.
We believe this study was very judgmental as the randomiza-
tionwaswell controlled, and baseline characteristics of both groups
regarding age, duration and type of infertility, and semen analysis
characteristics were all insigniﬁcantly variable between both
groups.
One disadvantage of the use of the gonadotropin antagonist
regimen was the very high direct cost (1600 ± 200 SR) compared
with only 50 ± 20 SR in the clomiphene group. Another disad-
vantage is the high risk of multiple pregnancies, yet, in the social
traditions in Arab countries, it is an advantage.
Another disadvantage with the antagonist protocol is the high
incidence of OHSS: 30 (10%) versus six (2%) in the clomiphene
group. However, all reported cases were mild and treated
conservatively.
We followed the usual time of IUI after hCG, as there is no
consensus about the best time suggested, although it has been
mentioned to be anywhere between 12 hours and 60 hours [14].
Although luteal phase support beneﬁt in cycles using antagonist
protocol is a matter of unproven research [15e18], we chose to
implement luteal support, as it might increase the pregnancy rate
[19,20]. Other studies showed that routine luteal-phase support by
vaginal suppositories did not improve pregnancy results in clomi-
phene citrate induced cycles in IUI trials [21] but an evidence-based
review recommended to apply luteal-phase support in stimulated
IUI cycles only when proven cost-effective [22].
Finally, because the pregnancy outcome of gonadotropin stim-
ulation is signiﬁcantly higher, it seemsmore reasonable to compare
the protocols with and without antagonists in future studies.Conclusions
In conclusion, this study was in favor of the routine use of the
antagonist protocol in patients with unexplained infertility un-
dergoing IUI procedure. This area of research still needs more in-
vestigations to examine other factors that may play a role in the
results of IUI.
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